The Clorox Company (CLX) drops 9% on profit outlook cut
The Clorox Company (CLX) drops sharply after cutting full-year profit guidance and warning that gross margins will weaken more than expected. The consumer staples name posted a mixed quarter, but investors are focusing on lower earnings power, margin pressure, and a tougher near-term outlook.
The Clorox Company (CLX) drops 9.3% after management cut its full-year profit outlook and warned that gross margins will fall far more than previously expected. The stock’s decline reflects a clear earnings reset, not market noise, and signals that investors are now valuing Clorox on a lower earnings base with weaker near-term margin support.
The Clorox Company (CLX) drops sharply today, down 9.33% to $87.44 as of 11:04 ET, while volume runs at 2.2x its 200-day average. For a consumer defensive stock with a 0.645 beta, that is not routine volatility. It is a direct repricing after Clorox cut its full-year profit outlook and warned that gross margins will weaken far more than it had forecast just one quarter ago.
Key Takeaways
CLX is sliding on an earnings-driven selloff, not on rumor or broad market noise.
The main catalyst is a lower FY2026 adjusted EPS outlook of $5.45 to $5.65, down from $5.95 to $6.30.
Gross margin guidance worsened to a 250 to 300 basis point decline, versus a prior expected drop of 50 to 100 basis points.
Q3 itself was mixed but not terrible: revenue was flat at $1.67B and adjusted EPS was $1.64, above consensus estimates cited in market summaries.
For investors, the issue is simple: Clorox still looks inexpensive on trailing earnings, but a lower earnings base and weaker margin profile can keep pressure on the stock.
What Is Driving The Clorox Company Stock Drop Today
The clearest reason for today's CLX selloff is the company's April 30 fiscal Q3 2026 earnings update and revised full-year outlook. Clorox reported Q3 revenue of $1.67B, up 0.1% from a year earlier, and adjusted EPS of $1.64. That topped consensus estimates cited by market reports, including a $1.48 EPS estimate and roughly $1.65B in revenue.
However, the market is not rewarding the quarter because the forward guide got hit hard. Clorox now expects FY2026 adjusted EPS of $5.45 to $5.65, down from prior guidance of $5.95 to $6.30. Just as important, the company now sees gross margin down 250 to 300 basis points for the year, far worse than its prior outlook for only a 50 to 100 basis point decline.
That kind of reset matters more than a modest earnings beat. Consumer staples stocks such as Clorox trade on stability, pricing power, and margin durability. When management tells the market that profits and margins are both moving the wrong way, the stock usually gets repriced fast. That is exactly what the tape is showing today.
Why Lower Margin Guidance Matters More Than A Q3 EPS Beat
Clorox's quarter was mixed, but the revised margin outlook is the real damage. Gross margin in Q3 fell 140 basis points year over year, and the full-year view got much worse. In plain English, Clorox is saying each sale is generating less profit than investors expected, and that pressure is broad enough to last through the fiscal year.
Reuters-linked market coverage tied the weaker outlook to softer demand, higher costs, higher energy expense, and costs related to GOJO. That combination is awkward for a defensive brand portfolio. A staples company can often absorb weak volumes if margins hold, or absorb margin pressure if volumes are strong. Clorox is dealing with pressure on both fronts.
There is also an ERP-related inventory effect muddying the year. Clorox said retailer inventory drawdown tied to the prior year's ERP transition is worth about 7.5 points of FY2026 sales decline and about $0.90 of EPS impact. That explains part of the weak year-over-year setup, but it does not erase the market's concern. Investors are being asked to look through a temporary sales distortion while also accepting a much weaker margin profile. That is a tough sell in any sector, especially in consumer staples where consistency is the whole product.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
After today's decline, Clorox carries a market cap of $10.57B, a trailing P/E of 15.784, and a dividend yield of 5.21%. On the surface, that valuation looks more reasonable than it did when the stock traded closer to its 52-week high of $133.34. Yet the stock is also below its stated 52-week low of $93.39, which shows how severe this reset has become.
The problem with calling CLX cheap too quickly is that trailing valuation can flatter a business just as earnings power is being revised down. If the new FY2026 adjusted EPS range of $5.45 to $5.65 becomes the market's anchor, then the stock is not being judged against the old profit base anymore. It is being judged against a lower one.
There is also a quality-versus-price debate here. Clorox still owns durable brands across cleaning, household, lifestyle, and international categories. That competitive position has real value. But a good business and a good stock are not always twins. Sometimes they are distant relatives, especially on a red day after guidance cuts.
Recent analyst actions show that Wall Street is also resetting expectations lower. On May 1, Barclays cut its price target to $85 from $102, UBS lowered its target to $96 from $110, Deutsche Bank moved to $91 from $100, and Evercore ISI cut its target to $110 from $115. Those target cuts did not create the problem, but they confirm that the earnings reset is changing how analysts value the shares.
GOJO Deal And Demand Pressure Add More Near Term Friction
Clorox completed its GOJO Industries acquisition on April 1, 2026. Strategically, adding Purell and related health and hygiene products fits the portfolio. Near term, though, the deal adds friction. Clorox said GOJO is expected to add about 3 points to net sales in FY2026 but dilute adjusted EPS by 2 to 4 cents, partly due to interest expense and a different margin structure.
That matters because investors usually want a consumer staples acquisition to look clean and accretive. Instead, GOJO arrives during a year already pressured by inventory normalization, weaker demand, and higher costs. So the acquisition reads less like a quick fix and more like another moving part in an already busy engine.
Meanwhile, the broader analyst backdrop is cautious. The consensus rating sits at Hold, with 19 Hold ratings and 5 Sell ratings against 4 Buy ratings. The consensus price target is $109.40, but today's analyst revisions show that target base is still moving lower after the earnings update.
What Today's High Volume Selloff Means For CLX Investors
The above-average volume matters because it shows institutions are reacting, not just retail traders. A 2.2x relative volume move in a low-beta staples name usually signals a serious change in expectations. This is not the market shrugging at a soft quarter. It is the market repricing CLX for lower margins and lower earnings.
Actionable insight starts with time frame. Income-focused investors will notice the 5.21% dividend yield and a stock that has already fallen hard. That setup can attract bargain hunters. Still, the cleaner setup usually comes after earnings cuts stop cascading through estimates and price targets. For shorter-term traders, the fact that Barclays now sits at an $85 target shows the stock is already trading near a bearish sell-side case. For longer-term investors, the more important issue is whether Clorox can stabilize margins after this guidance reset.
The bottom line is that today's CLX drop is rooted in a very specific problem: Clorox delivered a decent quarter, then told the market the rest of the year will be less profitable than expected. Until that margin story improves, the stock can stay under pressure even with a lower valuation and a high dividend yield. Defensive stocks are supposed to be boring. Right now, Clorox is being priced as anything but that.
CLX is down because Clorox cut its FY2026 adjusted EPS guidance and sharply lowered its gross margin outlook. Investors are selling the stock on weaker forward earnings power, even though Q3 revenue and EPS were mixed to slightly better than expected.
+Should I buy CLX stock now?
Not aggressively based on this update alone. The stock may look cheaper after the selloff, but the lower earnings outlook and weaker margins suggest the market still needs proof that profits are stabilizing.
+Did Clorox miss earnings this quarter?
No, the quarter was not a clear earnings miss. Reported Q3 revenue was essentially flat and adjusted EPS came in above the estimates cited in market coverage, but the stock fell because forward guidance was cut.
+What does the lower gross margin guidance mean for investors?
It means Clorox expects less profit from each dollar of sales than previously thought. That is a major concern for a consumer staples company because margin durability is a key part of its valuation.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on CLX?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
